123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease
Open Access
- 1 August 1999
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 67 (2) , 189-194
- https://doi.org/10.1136/jnnp.67.2.189
Abstract
OBJECTIVES 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson’s disease, (2) the usefulness of 123I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in 123I-MIBG myocardial scintigraphy, (4) the usefulness of 123I-MIBG myocardial scintigraphy to differentiate Parkinson’s disease from the other neurological diseases mimicking it. METHODS 123I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson’s disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy. RESULTS In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson’s disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson’s disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia. CONCLUSION 123I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson’s disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson’s disease.Keywords
This publication has 31 references indexed in Scilit:
- Sympathetic Cardioneuropathy in DysautonomiasNew England Journal of Medicine, 1997
- Autonomic Dysfunction in Parkinson's DiseaseEuropean Neurology, 1997
- Sympathetic skin response in Parkinson's diseaseActa Neurologica Scandinavica, 1996
- A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failureJournal of the Autonomic Nervous System, 1994
- Decreased 123I-MIBG uptake and increased clearance in various cardiac diseasesNuclear Medicine Communications, 1994
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Adrenergic supersensitivity in Parkinsonians with orthostatic hypotensionEuropean Journal of Clinical Investigation, 1990
- Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidineJournal of the American College of Cardiology, 1989
- Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathyJournal of the American College of Cardiology, 1988
- The hypothalamus in parkinson diseaseAnnals of Neurology, 1978